Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
about
PPARγ and the Innate Immune System Mediate the Resolution of InflammationBreaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticlesPeroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents.Type 2 diabetes and cardiovascular disease: getting to the fat of the matter.Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.Pleiotropic effects of thiazolidinediones.Rosiglitazone reduces urinary albumin excretion in type II diabetes.Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.
P2860
Q26771755-E89CB8BF-5E34-4A2D-9970-D1EEBC8FF1B8Q26830366-2712D799-AB19-44E9-84D7-C0C69D2C3308Q34342040-9C3CA247-4C44-423E-9289-7F3238604E95Q34421542-ED94496E-097C-4ADF-A61B-724CC6B91D1EQ34897476-0F8E8463-0C97-435B-9700-C1164A508DB3Q34986710-9E5A7595-3151-43AE-8818-DCAA4F3A2DF6Q36814772-F5EC5527-925C-4FB0-A9A0-FE456C2801A8Q36909303-7635FE0F-8AD5-4EB2-BCCF-06C8F88521FDQ37142044-7B77BD98-9358-4A3B-BF9D-5AF346E7E753Q44305174-1BD605FA-1143-4E31-8F88-7964520F2184Q51472462-BB5F04DA-23E6-4DE0-8D08-2489CA065C91
P2860
Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@en
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@nl
type
label
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@en
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@nl
prefLabel
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@en
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@nl
P2093
P1433
P1476
Improvement by the insulin-sen ...... s in type 2 diabetes mellitus.
@en
P2093
P304
P356
10.1016/S0026-0495(00)80045-1
P577
2000-05-01T00:00:00Z